+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Immunotherapy Drugs Market by Type, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889000
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immunotherapy Drugs Market grew from USD 175.64 billion in 2023 to USD 196.96 billion in 2024. It is expected to continue growing at a CAGR of 12.35%, reaching USD 397.02 billion by 2030.

Immunotherapy drugs, crucial in disease treatment, particularly cancer, have been revolutionizing modern medicine by enhancing the body's natural defense mechanisms to fight diseases more effectively. Their scope encompasses monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and non-specific immunotherapies. These drugs are necessary as they offer a targeted approach, potentially leading to fewer side effects than traditional methods like chemotherapy or radiation. Their applications extend beyond oncology, finding use in treating autoimmune disorders, infectious diseases, and even allergies. The primary end-use scope involves personalized medicine, hospitals, clinics, and research institutions focused on advanced therapeutic treatments. Growth in this market is driven by an increasing prevalence of chronic diseases and a rising emphasis on precision medicine, supported by advancements in biotechnology and genomic studies. The latest opportunities include developing combination therapies, minimizing immunogenic responses, and exploring less resource-intensive drug development techniques. To seize these opportunities, companies should invest in R&D partnerships, focus on biomarker identification, enhance clinical trial designs, and engage in strategic collaborations with academic and research organizations. However, challenges like high development costs, stringent regulatory pathways, and potential adverse immune reactions limit growth. Furthermore, intellectual property issues and the complexities of clinical trial designs remain pressing concerns. Therefore, innovation should prioritize enhancing the safety and efficacy profile of immunotherapy drugs, developing cost-effective manufacturing processes, and exploring artificial intelligence and machine learning to accelerate discovery and development cycles. The market is highly dynamic, demanding continuous surveillance of scientific breakthroughs, regulatory changes, and competitive landscapes to maintain relevance, adapt strategies, and forecast future trends accurately. Businesses should aim for a balance between innovation, compliance, and cost-effectiveness to thrive in the evolving immunotherapy landscape.

Understanding Market Dynamics in the Immunotherapy Drugs Market

The Immunotherapy Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • The rising incidence of chronic diseases globally
    • Increasing approval and launch of new immunotherapy drugs
    • Growing demand for personalized medicine among consumers
  • Market Restraints
    • Complex and lengthy approval processes
  • Market Opportunities
    • Growing government emphasis on development of advanced immunotherapy drugs
    • Rising investments from private sectors and emerging biotech startups
  • Market Challenges
    • Emerging safety concerns of side effects of drugs

Exploring Porter’s Five Forces for the Immunotherapy Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Immunotherapy Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Immunotherapy Drugs Market

External macro-environmental factors deeply influence the performance of the Immunotherapy Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Immunotherapy Drugs Market

The Immunotherapy Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Immunotherapy Drugs Market

The Immunotherapy Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Immunotherapy Drugs Market

The Immunotherapy Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Affimed Therapeutics, AstraZeneca PLC, Atara Biotherapeutics, Biogen Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., ElevateBio, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samyang Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Turnstone Biologics.

Market Segmentation & Coverage

This research report categorizes the Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Cancer Vaccines
    • Checkpoint Inhibitors
    • Cytokines-Based Therapy
    • Monoclonal Antibodies
    • T-cell Therapy
  • Application
    • Autoimmune Disease
    • Infectious Disease
    • Neurology
    • Oncology
  • End-User
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. The rising incidence of chronic diseases globally
5.1.1.2. Increasing approval and launch of new immunotherapy drugs
5.1.1.3. Growing demand for personalized medicine among consumers
5.1.2. Restraints
5.1.2.1. Complex and lengthy approval processes
5.1.3. Opportunities
5.1.3.1. Growing government emphasis on development of advanced immunotherapy drugs
5.1.3.2. Rising investments from private sectors and emerging biotech startups
5.1.4. Challenges
5.1.4.1. Emerging safety concerns of side effects of drugs
5.2. Market Segmentation Analysis
5.2.1. Type: Growing demand for cancer vaccines with the rising prevalence of cancer
5.2.2. Application: Emerging application for autoimmune disease therapy
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Immunotherapy Drugs Market, by Type
6.1. Introduction
6.2. Cancer Vaccines
6.3. Checkpoint Inhibitors
6.4. Cytokines-Based Therapy
6.5. Monoclonal Antibodies
6.6. T-cell Therapy
7. Immunotherapy Drugs Market, by Application
7.1. Introduction
7.2. Autoimmune Disease
7.3. Infectious Disease
7.4. Neurology
7.5. Oncology
8. Immunotherapy Drugs Market, by End-User
8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics
9. Americas Immunotherapy Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immunotherapy Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Immunotherapy Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Hanmi Pharmaceutical and Merck forge partnership to pioneer synergistic immunotherapy for advanced cancer treatment
12.3.2. Pathios Therapeutics secures USD 25 Million in series B to propel immunotherapy treatments into clinical trials and drive long-term oncology innovations
12.3.3. Pfizer acquires Seagen to accelerate innovative cancer therapies with advanced ADC technology, strengthening leadership in oncology and expanding global impact
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. IMMUNOTHERAPY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Immunotherapy Drugs market, which are profiled in this report, include:
  • AbbVie Inc.
  • Affimed Therapeutics
  • AstraZeneca PLC
  • Atara Biotherapeutics
  • Biogen Inc.
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celldex Therapeutics
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • ElevateBio
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Turnstone Biologics

Methodology

Loading
LOADING...

Table Information